After three terms in the U.S. House and two unsuccessful campaigns for the U.S. Senate, Colin Allred said he’s heard plenty about voters’ suspicions that politicians are just trying to make a buck in Washington. The post Democrats feud over stock trading as they sharpen anti-corruption case against Trump appeared first on The Dispatch .
TYSONS CORNER, Va.--(BUSINESS WIRE)--Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR; LuxSE: STRE) (“Strategy”) today announced the completion of a series of capital-markets and bitcoin transactions executed over the period May 11-25, 2026. These transactions include the previously disclosed repurchase of $1.5 billion aggregate principal amount of its 0% Convertible Senior Notes due 2029 (2029 Notes), the use of cash reserves for this purpose, and sales of Digital Equity (MSTR) and Digital Credi
BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5.0M (the "Financing"). Proceeds from the Financing will be used to bolster the Company’s digital asset treasury and will provide working capital in support of a comprehensive strategic review. With the anticipated proceeds, the Company expects to hold over $16.4M
EASTON, Md., May 26, 2026 (GLOBE NEWSWIRE) -- TeraWulf Inc. (NASDAQ: WULF ) ("TeraWulf" or the "Company"), which owns and operates vertically integrated, next-generation digital infrastructure, today announced the acquisition of a hyperscale high-performance computing ("HPC") development site strategically located in Eastern Kentucky (the "Muskie Data Campus"). The acquisition meaningfully expands TeraWulf's portfolio of large-scale, energy-advantaged digital infrastructure campuses and advances the Company's strategy of developing shovel-ready AI and HPC sites with long-term power availability, robust transmission infrastructure, and strong community alignment. The Muskie Data Campus, acquired from Industrial Equity Partners ("IEP"), is expected to support more than 1 gigawatt ("GW") of data center capacity over time. Delivery of the initial 500 megawatts ("MW") is expected to ramp beginning in the second half of 2028, with an additional 500 MW targeted for delivery in the second half of 2030. Jake Bronstein and Michael MacDougall, speaking on behalf of IEP, said, "We have long believed the Muskie Data Campus represented a compelling opportunity for large-scale digital infrastructure development in Eastern Kentucky. We believe TeraWulf brings the infrastructure expertise, power strategy, and execution capabilities needed to realize the project's full potential." Located within the 1,000-acre EastPark Industrial Park, the site includes approximately 285 acres of owned and controlled land capable of supporting hyperscale AI and HPC infrastructure, with optional adjacent acreage to support future expansion. Regional economic development leaders have identified the project as one of the most significant economic development opportunities in northeastern Kentucky in decades. Kentucky Power, an AEP Company, is constructing a 345 kV substation connected to the existing 765 kV transmission network, providing redundant, utility-scale power infrastructure designed to support the full 1+ GW campus. Transmission infrastructure and energy service agreements were executed concurrently with the acquisition pursuant to the applicable Industrial General Service tariff structure for large loads, establishing a clear pathway to long-term, large-scale power delivery. The site is already zoned for its intended use, with permitting activities underway and limited site work required to support data center construction. The Company believes the Muskie Data Campus provides a clear line of sight to near-term construction commencement and accelerated time-to-power relative to many competing development opportunities. TeraWulf intends to work collaboratively with regional educational and workforce development institutions to support workforce training and long-term economic development initiatives associated with the Muskie Data Campus. Management Commentary "This acquisition further reinforces the strategy we discussed ... Full story available on Benzinga.com
NEW YORK--(BUSINESS WIRE)--BitGo, Inc., the digital asset infrastructure company and wholly owned subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), and Silence Laboratories Pte. Ltd (“Silence Laboratories”) today announced a strategic collaboration to develop quantum-safe multi-party computation, or MPC, wallet infrastructure for institutional digital asset custody and transaction signing. As part of the collaboration, the companies completed the first post-quantum transaction simulati
Once the undisputed symbol of luxury, natural diamonds face an existential challenge from laboratory-grown synthetics. They are a cheaper alternative, more accessible and are marketed as ethically superior. Prices of natural diamonds have slipped, demand has softened. Even gem giants like De Beers are reporting losses. In this climate, African producers, most notably Botswana, have [...] The post Africa’s Place in the Global Diamond Economy appeared first on The Namibian .
BitMEX and COLLYBUS today announced a partnership providing professional and active traders with access to institutional-grade trading technology.
Urges Stockholders to Vote " FOR " the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX ) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following statement with important facts stockholders should know regarding Pacira's intellectual property (IP) strategy, and DOMA Perpetual Capital Management LLC's ("DOMA Perpetual" or "DOMA") 1 recent inaccurate statements: DOMA's claims demonstrate a fundamental lack of understanding of Pacira's business, intellectual property (IP) strategy, Paragraph IV certifications and the biopharmaceutical industry at large. Pacira has clearly and frequently communicated information regarding patent awards or infringement litigation to its stockholders and remains committed to doing so. Pacira strongly believes in the strength of the EXPAREL franchise, and its patent estate protects the Company from multiple directions. Here are the facts: Pacira's initial patent litigation commenced in 2021 and continued through 2024. There is no precedential value to this case , which only involved one EXPAREL patent (the ‘495 patent). The ‘495 patent was litigated in the United States District Court for the District of New Jersey. Following the Court's decision, Pacira secured a favorable reexamination of its ‘495 patent from the U.S. Patent and Trademark Office (USPTO). Importantly, during this process, any weakness in this patent, which is from the Erucic Acid Family, was addressed through amended claims that added volume limitations and resolved other issues noted in the New Jersey Court's opinion. The ‘495 patent has been reissued, and the Company believes it is now the strongest in the Erucic Acid Family of patents. None of EXPAREL's "Orange Book" listed patents are manufacturing patents. The 21 patents currently listed in the Orange Book comprise chemical composition and product-by-process patents covering the drug product, as well as method-of-use patents. Manufacturing patents are not Orange Book listable by statute. Pacira engineered a new enhanced, larger-scale EXPAREL manufacturing process in San Diego that produced a more consistent and stable multivesicular liposome with improved yield and particle-size distribution. Because these results were unexpected, this was a patentable invention and became the ‘940 patent, which provides protection into July 2044. The ‘940 patent is the first of a new , second family of EXPAREL patents that has never been previously challenged or litigated. While the Company believes the Erucic Acid Family is strong, Pacira believes this second patent family is even stronger. The novelty of the ‘940 patent and its family derives from the large dataset of in vitro release assay (IVRA) batch data measured from every batch of EXPAREL . A separate USPTO examiner from the first family allowed the patent after considering the Court's opinion in the ‘495 patent litigation. The Fresenius Kabi Settlement was a strategic win for stockholders , giving Pacira full exclusivity for EXPAREL through early 2030 and a gradual, capped market entry until 2039. This presents a clear runway to execute Pacira's diversification strategy without the rapid decline and disruption normally seen with generic entry. Pacira has taken critical steps to strengthen its IP and mitigate litigation risk, including expanding EXPAREL's patent estate to 21 Orange Book listed patents across two families , which provide exclusivity through the mid-2040s. The Company expects additional patents to be issued, which will be added to this robust patent estate. The potential for additional generic competition is a common dynamic with successful products like EXPAREL and is inherent to the biopharmaceutical industry. Pacira continues to innovate with the expectation that additional patents will be issued. Importantly, the two most recent Paragraph IV generic challenges only mean that Abbreviated New Drug Applications (ANDAs) have been filed with the U.S. Food and Drug Administration (FDA) . It does not mean these generic challengers have FDA approvable products with demonstrated bioequivalence to EXPAREL that have been manufactured at commercial scale . A Paragraph IV challenge is a gatekeeping standard for the FDA to accept an ANDA for filing and occurs before a substantive review takes place. The Company is in the early stages of this litigation, and as an active legal matter Pacira is limited in what it can say. Pacira has filed a patent infringement lawsuit in the United States District Court for the District of Delaware. The IVRA family has never ... Full story available on Benzinga.com
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Frequency Electronics, Inc. is evolving from a niche timing supplier into a backlog-conversion and operating-leverage story. Read why FEIM stock is a Buy.
Aduro to commence trading on the TSX under ACT, marking its next capital markets step while maintaining Nasdaq and Frankfurt listings.
1-for-50 reverse split of common shares outstanding now complete